In this episode, a panel of experts discuss existing VTE treatment options, algorithms, corresponding safety and efficacy profiles along with safety and efficacy data, and protocols to address treatment pathways. Claim CE and MOC Credit at https://bit.ly/VTEIII ..read more

COVID-19 care is now mostly provided outside of hospital settings. Early diagnosis and therapeutic intervention for those who are at increased risk of progression to severe COVID-19 may improve outcomes. Dr. Jeff Hsu talks with Dr. Mary Brennan about the symptoms associated with the different stages of SARS-CoV-2 and choosing the appropriate outpatient therapeutic treatment.   CE and ABIM MOC credits available: https://bit.ly/3PeZRIy     ..read more

Conversation about the approved GLP-1 RAs to manage type 2 diabetes mellitus (T2DM). Forms of administration, contextualizing the many benefits and the risks, and indications will be discussed. Claim CE Credit at https://bit.ly/49Ultlu ..read more

Conversation about the global rise of obesity and its association with diabetes and the limited effectiveness of many pharmacotherapies tested for management of obesity. You will also learn about weight loss benefits, improvement in cardiovascular risk factors, and potential for cardiovascular event reduction with GLP-1RA therapy in patients with obesity.  Claim CE Credit at https://bit.ly/3OkYJm9 ..read more

Conversation around current considerations for use of GLP-1 RAs in people with type 2 diabetes and chronic kidney disease (CKD). The discussion will include general considerations for management of diabetes in CKD, potential benefits of GLP-1 RA therapy in CKD (e.g., glycemic lowering, CV risk reduction, potential kidney benefits), and a discussion of contemporary guideline recommendations for GLP-1 RA use in this population. Claim CE and MOC Credit at https://bit.ly/4aNc3t8 ..read more

Conversation around specific cardiovascular risks, while distinguishing between glycemic control and cardiovascular risk reduction. We will also highlight the benefits of treatment with GLP-1 RA in patients with diabetes. Claim CE and MOC Credit at https://bit.ly/45mZkdq ..read more

This activity focuses on the American Heart Association’s Essential 8 and glucose control. You will learn how GLP-1 RAs accelerate these glucose control goals and contribute to cardiorenal outcomes including how they work. Claim CE and MOC Credit at https://bit.ly/47nTdqQ ..read more

HCM experts discuss the importance of shared decision-making in the treatment of patients with HCM with or at risk for arrhythmias, including patient perspectives. The prevalence of symptomatic and asymptomatic atrial fibrillation requires shared decision-making between patients and providers regarding initiation of oral anticoagulation and global management strategy (rate vs rhythm control). Likewise, this episode will highlight factors to consider when deciding on ICD placement, particularly for primary prevention of sudden cardiac death ..read more

When patients present with symptoms such as fatigue, fainting, shortness of breath, chest pain or heart palpitations without a known cause, suspect and test for HCM. In this episode, experts will discuss the best approaches for the management of symptoms in patients with HCM.  Lean more on identifying strategies to improve provider-patient communication and utilizing shared decision-making to personalize treatment strategies.  ..read more

In this episode, a panel of experts discuss identifying appropriate risk assessment strategies to accurately determine the level of VTE risk for patients ..read more